Endorphins, Enkephalins, and Dynorphins Explained

Beta-Endorphin and Endogenous Opioids

3 peptide families

The human body produces over 20 distinct opioid peptides from three precursor proteins, each targeting different receptor subtypes to modulate pain, mood, stress, and reward.

Conway et al., Addiction Neuroscience, 2022

Conway et al., Addiction Neuroscience, 2022

View as image

Your body manufactures its own painkillers. Not one type, but three distinct families of opioid peptides: endorphins, enkephalins, and dynorphins. Together, these molecules make up the endogenous opioid system, a signaling network that modulates pain perception, emotional states, stress responses, feeding behavior, and reward processing across virtually every organ system. Over 20 unique opioid peptides have been identified from four precursor molecules, each with distinct receptor preferences and tissue distributions.^[1] This article covers how these three peptide families differ in structure, where they act, what they do, and where the boundaries of current knowledge lie. For a deep look at the most studied member of these families, see our pillar article on beta-endorphin.

Three precursor proteins, three peptide families

All endogenous opioid peptides are derived from larger precursor proteins that are cleaved by enzymes into their active forms. Each precursor gene produces a different family of opioid peptides with distinct receptor preferences. Tache et al. (2024) mapped the four endogenous opioid peptide families and their receptor targets, establishing that beta-endorphin, enkephalin, dynorphin, and endomorphin each act through multiple receptor types (mu, delta, kappa, and ORL1) with overlapping but distinct affinities.^[4]

Proopiomelanocortin (POMC) gives rise to beta-endorphin, a 31-amino acid peptide. POMC is expressed primarily in the arcuate nucleus of the hypothalamus and the anterior pituitary gland. The same precursor also produces adrenocorticotropic hormone (ACTH) and alpha-melanocyte-stimulating hormone, linking beta-endorphin production directly to the stress response. When the hypothalamic-pituitary-adrenal axis activates, it releases both stress hormones and analgesic peptides simultaneously.

Proenkephalin (PENK) produces the enkephalins: met-enkephalin (Tyr-Gly-Gly-Phe-Met) and leu-enkephalin (Tyr-Gly-Gly-Phe-Leu). Each proenkephalin molecule contains four copies of met-enkephalin, one copy of leu-enkephalin, plus an octapeptide and a heptapeptide. Enkephalins are the smallest opioid peptides at just five amino acids, and they are distributed throughout the brain, spinal cord, and adrenal medulla.

Prodynorphin (PDYN) yields dynorphin A, dynorphin B, and neoendorphin. These peptides contain the leu-enkephalin sequence at their amino terminus but have extended carboxyl-terminal tails that dramatically alter their receptor binding profile. Goldstein et al. (1979) first characterized dynorphin-(1-13) from porcine pituitary and found it approximately 700 times more potent than leu-enkephalin in the guinea pig ileum assay.^[3] The extended arginine- and lysine-rich tail is responsible for this dramatic potency increase and for dynorphin's strong preference for kappa-opioid receptors.

All three families share a common amino-terminal motif: Tyr-Gly-Gly-Phe-Met (or Leu). This five-residue "opioid motif" is the minimum structural requirement for binding to opioid receptors. What distinguishes the families from each other is everything that extends beyond this shared core.

How they bind: receptor preferences and biased signaling

The three classical opioid receptor types, mu (MOR), delta (DOR), and kappa (KOR), each have a preferred endogenous ligand, though the selectivity is relative rather than absolute.

Beta-endorphin binds preferentially to mu-opioid receptors. Mu activation produces analgesia, euphoria, reward reinforcement, respiratory depression, and reduced gastrointestinal motility. The mu receptor is the primary target of exogenous opioid drugs like morphine and fentanyl, which is why beta-endorphin is sometimes called "the body's own morphine."

Enkephalins bind preferentially to delta-opioid receptors, though they also activate mu receptors. Delta activation produces analgesia with a different quality than mu activation: less euphoria, less respiratory depression, and potentially neuroprotective effects. Enkephalins also modulate neurotransmitter release at synapses throughout the central nervous system, acting as neuromodulators that fine-tune transmission rather than carrying signals themselves.

Dynorphins bind preferentially to kappa-opioid receptors. Kappa activation is pharmacologically distinct from mu and delta activation: it produces analgesia but also dysphoria (the opposite of euphoria), sedation, and aversive states. This makes the dynorphin/kappa system functionally antagonistic to the beta-endorphin/mu system in emotional processing. Where beta-endorphin signals reward, dynorphin signals distress.

Thompson et al. (2015) demonstrated that this receptor preference model, while useful, is an oversimplification. Endogenous opioid peptides display biased agonism at the mu-opioid receptor: different peptides activate different intracellular signaling cascades through the same receptor. Alpha-neoendorphin, Met-enkephalin-Arg-Phe, and endomorphin-1 each produced distinct patterns of G protein activation and beta-arrestin recruitment compared to the synthetic reference agonist DAMGO. This means the biological effect of activating a mu receptor depends on which endogenous peptide does the activating.^[5]

Abrimian et al. (2021) added another layer of complexity. The mu-opioid receptor gene (OPRM1) produces multiple splice variants with different carboxyl-terminal sequences, and endogenous opioid peptides show variant-specific pharmacological profiles across these splice variants, with distinct patterns of receptor binding, G protein activation, and beta-arrestin2 recruitment.^[7] The cellular response to a given opioid peptide therefore depends on both the peptide identity and the receptor variant expressed in that tissue.

Where they act: distribution throughout the body

The three opioid peptide families have overlapping but distinct anatomical distributions, reflecting their different functional roles.

Enkephalins have the widest distribution of any opioid peptide family. They are found in the dorsal horn of the spinal cord (laminae I, II, and V), where they modulate incoming pain signals; in the periaqueductal gray (PAG), the brainstem region that coordinates descending pain inhibition; in the limbic system, where they participate in emotional processing; in the basal ganglia, where they modulate motor function; and in the adrenal medulla, where they are co-released with catecholamines during stress. Bagley and Ingram (2020) mapped the role of endogenous opioid peptides in the descending pain modulatory circuit, demonstrating that enkephalins in the PAG and rostral ventromedial medulla are critical components of the brain's top-down pain control system.^[9]

Beta-endorphin has a more restricted distribution. It is produced primarily in two locations: the arcuate nucleus of the hypothalamus and the nucleus of the solitary tract in the brainstem. From these sites, beta-endorphin-containing neurons project widely to other brain regions, including the PAG, the amygdala, and the nucleus accumbens (the brain's reward center). The pituitary gland also releases beta-endorphin into the bloodstream as a hormone, giving it a dual neuromodulatory and endocrine role.

Dynorphins are concentrated in the hypothalamus, the hippocampus, the spinal cord dorsal horn, and the striatum. Their presence in the hippocampus is linked to stress-related memory modulation, while their spinal cord distribution contributes to local pain processing. Dynorphins are also found in the nucleus accumbens, where their kappa receptor activation produces aversive states that counterbalance mu receptor-mediated reward.

This differential distribution has functional consequences. In the spinal cord dorsal horn, all three families are present and can modulate pain transmission through different receptor types simultaneously. In the reward circuit, beta-endorphin and dynorphin produce opposing effects through their preferred receptors, creating a push-pull system that balances approach and avoidance behaviors.

Pain modulation: three systems, one outcome

The endogenous opioid system's most studied function is pain modulation, and all three peptide families contribute through distinct mechanisms.

Holden et al. (2005) reviewed how the endogenous opioid system provides the biological foundation for clinical pain management, demonstrating that endorphins, enkephalins, and dynorphins work in concert: understanding their distinct mechanisms improves the rationale for opioid drug selection and dosing strategies in clinical settings.^[10]

Enkephalins operate primarily in the spinal cord and brainstem. In the dorsal horn, enkephalin-containing interneurons form synapses directly on pain-transmitting neurons, releasing enkephalins that activate delta (and mu) receptors to inhibit pain signal transmission. This mechanism is local and rapid. Enkephalins are also critical components of the descending pain modulatory system: neurons in the PAG and rostral ventromedial medulla use enkephalins to suppress spinal cord pain transmission from the top down.^[9] Because enkephalins are rapidly degraded by enkephalinases (enzymes that cleave the Gly-Phe and Gly-Gly bonds), their analgesic effects are brief and localized.

Beta-endorphin produces longer-lasting, more diffuse analgesia. Released from the hypothalamus and pituitary during stress and exercise, it provides a systemic analgesic signal. The duration of stress determines which opioid system is recruited. Parikh et al. (2011) showed that short-duration stress activated non-opioid analgesic mechanisms, while prolonged stress specifically recruited endogenous opioid peptide pathways, with the transition mediated by the hypothalamic-pituitary-adrenal axis that controls beta-endorphin release.^[11]

Dynorphins modulate pain through kappa receptors in the spinal cord and brainstem, but their role is more complex. While kappa activation can produce analgesia, dynorphin release in chronic pain states can paradoxically contribute to pain maintenance. Higginbotham et al. (2022) reviewed how chronic pain alters the endogenous opioid system, noting that persistent pain states are associated with upregulated dynorphin expression in the spinal cord, which may shift from a protective analgesic role to a pronociceptive one, contributing to central sensitization and chronic pain.^[12]

Beyond pain: mood, reward, feeding, and immunity

Pain modulation is the most studied function of endogenous opioids, but these peptide families regulate multiple other physiological systems.

Reward and mood. Beta-endorphin activation of mu receptors in the nucleus accumbens and ventral tegmental area produces reward signaling and positive affect. Dynorphin activation of kappa receptors in the same regions produces the opposite: dysphoria, anxiety, and aversion. This opponent process creates a homeostatic system where reward is balanced by aversion. The dynorphin/kappa system has been implicated in the negative emotional states that follow drug withdrawal and in stress-induced depression.

Feeding behavior. Bodnar (2019) reviewed decades of evidence showing that endogenous opioids regulate food intake and body weight, with implications for obesity and addiction. Mu and delta receptor activation in the hypothalamus and nucleus accumbens generally stimulates feeding, particularly of palatable, high-fat foods. Kappa receptor activation has more variable effects on feeding depending on the brain region. Opioid receptor antagonists like naltrexone reduce food intake, confirming that tonic endogenous opioid signaling maintains appetite.^[13]

Immune function. Endogenous opioids modulate immune cell activity, and immune cells themselves are a source of opioid peptides at sites of inflammation. Petrocelli et al. (2022) found that endogenous opioids modulate stem cell proliferation and differentiation, suggesting their biological role extends into tissue repair and regeneration beyond classical neuromodulation.^[14]

Acupuncture. Han (2004) demonstrated that acupuncture-induced analgesia operates through frequency-specific release of endogenous opioid peptides. Low-frequency electroacupuncture (2 Hz) releases enkephalins and beta-endorphin, producing analgesia through mu and delta receptors. High-frequency stimulation (100 Hz) releases dynorphins, producing analgesia through kappa receptors. This frequency-dependent selectivity provided some of the earliest evidence that the three opioid families could be differentially activated by external stimuli.^[8]

Regulation and cross-talk between families

Gupta et al. (2021) examined how endogenous opioid peptides regulate opioid receptor expression by studying mice lacking beta-endorphin, proenkephalin, or both. Loss of one peptide family did not trigger compensatory upregulation of others. Instead, the researchers found differential, region-specific, and sex-specific modulation of mu, delta, and kappa opioid receptor expression and activity.^[6] This means each opioid peptide family has an independent, non-redundant role in maintaining the receptor landscape, and the loss of one family creates deficits that are not filled by the remaining systems.

Cesselin (1995) introduced the concept of anti-opioid peptides: endogenous molecules that counterbalance opioid effects and may drive tolerance. Cholecystokinin (CCK), neuropeptide FF, and nociceptin/orphanin FQ all oppose the analgesic effects of endogenous opioids, creating a system of checks and balances. This anti-opioid system may explain why chronic opioid exposure (endogenous or exogenous) leads to tolerance: the anti-opioid peptides upregulate in response to sustained opioid signaling, progressively reducing the analgesic effect.^[15]

Terenius (2000) reviewed the historical trajectory from opiate pharmacology to opioid peptide physiology, noting that the pharmacological uniqueness of opiates implied that endogenous opioid ligands must exist, a prediction confirmed by the discovery of enkephalins, beta-endorphin, and dynorphins. He emphasized that despite decades of research, the full complexity of endogenous opioid cross-talk, with multiple peptides acting through multiple receptor subtypes with biased signaling at each, remains only partially mapped.^[16]

What remains uncertain

The endogenous opioid system has been studied for 50 years, but significant gaps persist.

Measurement remains a core limitation. Conway et al. (2022) cataloged the analytical challenges: traditional immunoassays cannot reliably distinguish between opioid peptides that share the opioid motif, mass spectrometry approaches are technically demanding, and in vivo measurements of opioid release in the human brain remain limited to indirect PET imaging methods. Quantitative claims about opioid peptide levels in response to specific stimuli should be interpreted within these methodological constraints.^[1]

The functional significance of biased agonism is still being established. Thompson et al. (2015) showed that different endogenous peptides activate different signaling pathways through the same receptor, but translating these in vitro observations into predictions about in vivo behavior remains difficult.^[5]

The interaction between endocannabinoid and opioid systems adds another dimension of complexity. Both systems modulate pain and reward, they share anatomical territory, and there is evidence of functional cross-talk between cannabinoid and opioid receptors. Mapping these interactions remains an active research frontier.

Asokan et al. (2025) provided an updated overview of opioid peptide sources and molecular sequences, highlighting that even the basic catalog of endogenous opioid peptides continues to expand as analytical methods improve.^[17]

The Bottom Line

The endogenous opioid system consists of three peptide families, each derived from a distinct precursor protein, with different receptor preferences and tissue distributions. Endorphins, enkephalins, and dynorphins work in concert to modulate pain, mood, reward, stress responses, and feeding behavior. Their distinct receptor binding profiles, biased signaling properties, and non-redundant functions create a signaling system of considerable complexity that is still being mapped after five decades of research.

Frequently Asked Questions

What is the difference between endorphins and enkephalins?

Endorphins and enkephalins are both endogenous opioid peptides, but they differ in size, source, and receptor preference. Beta-endorphin is a 31-amino acid peptide derived from proopiomelanocortin (POMC) that primarily binds mu-opioid receptors. Enkephalins are five-amino acid peptides derived from proenkephalin (PENK) that primarily bind delta-opioid receptors. Enkephalins act locally in the spinal cord and brainstem with short duration, while beta-endorphin has broader, longer-lasting effects through both central and hormonal release from the pituitary gland.

What do dynorphins do in the body?

Dynorphins are endogenous opioid peptides that primarily activate kappa-opioid receptors. They produce analgesia but also dysphoria, sedation, and aversive emotional states. Dynorphin-(1-13) is approximately 700 times more potent than leu-enkephalin in bioassay, as established by Goldstein et al. (1979). Dynorphins are concentrated in the hypothalamus, hippocampus, spinal cord, and striatum. Their role in chronic pain is complex: they can shift from a protective analgesic function to a pronociceptive one in persistent pain states.

Are endorphins the same as opioids?

Endorphins are endogenous opioids, meaning they are opioid peptides produced naturally by the body. They bind to the same receptors as exogenous opioid drugs like morphine and fentanyl. The term "endorphin" is a contraction of "endogenous morphine." Beta-endorphin acts primarily at mu-opioid receptors and produces analgesia and euphoria through the same molecular mechanism as pharmaceutical opioids, but with regulated release and rapid enzymatic degradation that prevents the sustained receptor activation caused by exogenous drugs.

How are endogenous opioid peptides released?

Endogenous opioid peptides are released in response to specific physiological stimuli. Beta-endorphin is released by the pituitary gland and hypothalamic neurons during stress, exercise (above approximately 70% VO2max), and pain. Enkephalins are released from interneurons in the spinal cord and brainstem during pain signal processing. Han (2004) showed that acupuncture selectively releases different opioid families depending on stimulation frequency: low frequency (2 Hz) releases enkephalins and beta-endorphin, while high frequency (100 Hz) releases dynorphins.

What happens when endogenous opioids are deficient?

Gupta et al. (2021) demonstrated that loss of beta-endorphin or proenkephalin causes region-specific and sex-specific changes in opioid receptor expression, with no compensatory increase from remaining peptide families. Clinically, reduced endogenous opioid tone has been associated with increased pain sensitivity, altered stress responses, and changes in reward processing. The lack of compensatory cross-regulation means that deficiency in one opioid peptide family produces functional gaps that cannot be filled by the other two families.

Do endorphins, enkephalins, and dynorphins affect mood?

Each family has distinct mood effects through their preferred receptors. Beta-endorphin activation of mu-opioid receptors produces euphoria and positive affect, which is the basis of the "runner's high." Enkephalin activation of delta receptors contributes to anxiolytic effects with less pronounced euphoria. Dynorphin activation of kappa receptors produces dysphoria and aversion, functionally opposing the mood effects of beta-endorphin. This creates a balanced system where reward signaling through mu receptors is counterbalanced by aversive signaling through kappa receptors.